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Abstract
 
Serum immunoglobulin (Ig)M provides the initial response to foreign antigen and plays a regu-
latory role in subsequent immune response development, accelerating the production of high-
affinity IgG. Here we show that mice deficient in serum IgM have an increased propensity to
spontaneous autoimmunity as judged by the development with age of serum IgG anti-DNA
antibodies and the renal deposition of IgG and complement. They also exhibit augmented anti-
DNA IgG production on exposure to lipopolysaccharide. Thus, deficiency in serum IgM leads
to diminished responsiveness to foreign antigens but increased responsiveness to self—a para-
doxical association reminiscent of that described in humans deficient in complement or IgA.
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Introduction
 
The first antibody to be produced after initial antigen en-
counter is of the IgM class. In addition to providing this
first line of specific defence, serum IgM also assists subse-
quent development of the immune response. Thus, while
mice deficient in the secretory form of IgM harbor rela-
tively normal numbers of surface IgM
 
1
 
, IgD
 
1
 
 B cells with
the serum titers of other Ig isotypes being largely unaf-
fected, they nevertheless exhibit delayed development of
specific IgG antibodies to T cell–dependent foreign antigens
(1, 2). Presumably, antigen–IgM complexes act through the
complement system either to facilitate antigen localization
to sites suitable for subsequent immune response develop-
ment or to costimulate B cell activation through the
CD21–CD19 receptor complex.
We wondered whether serum IgM might play an analo-
gous role with regard to the response to self-antigens.
However, here—in contrast to the sluggish response to for-
eign antigens—we find that deficiency in serum IgM actu-
ally predisposes to the development of IgG antibodies to
autoantigens.
 
Materials and Methods
 
The generation of CCB embryonic stem cell lines in which
the C
 
m
 
 secretory tailpiece and the 
 
m
 
s
 
 polyadenylation site have
been deleted on one allele by Lox/Cre-mediated gene targeting
has been described previously (2). The litters of 
 
m
 
s
 
2
 
/
 
m
 
s
 
2
 
 and
 
m
 
s
 
1
 
/
 
m
 
s
 
1
 
 mice used in this work are from the F2 generation ob-
tained by intercrossing 
 
m
 
s
 
1
 
/
 
m
 
s
 
2
 
 heterozygotes generated by
breeding embryonic stem cell–derived chimeras (created using
C57BL/6 blastocysts) with C57BL/6 females. Mice were housed
in a barriered specific pathogen–free facility with sentinel animals
from each room screened quarterly for a variety of potential
pathogens according to the recommendations of the Federation
of European Laboratory Animal Science Associations.
Serum titers of IgG anti–double-stranded (ds)DNA (S1 nu-
clease treated) were measured as described by Mohan et al. (3) us-
ing alkaline phosphatase–conjugated goat anti–mouse IgG
(Southern Biotechnology Associates). The assays were calibrated
using serum from a 7-mo-old NZB/W mouse, which was arbi-
trarily assigned a titer of 0.5 U/ml. Total IgG was measured by
ELISA calibrating with a monoclonal IgG1 (Sigma Chemical
Co.). Sera (diluted 1:20) were also titered by immunohistochem-
istry for antibody binding to 
 
Crithidia lucullia 
 
using FITC-conju-
gated goat anti–mouse IgG (Southern Biotechnology Associates).
Antibodies to cardiolipin and myeloperoxidase were monitored
by ELISA, and surface plasmon resonance was performed as de-
scribed previously (4). Glomerular histology was assessed on peri-
odic acid-Schiff–stained sections of kidney fixed in Bouin’s fixa-
tive and embedded in paraffin. Immunofluorescence microscopy
was performed on cryostat sections of kidneys that had been
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snap-frozen in an 
 
N
 
-hexane/dry ice bath using FITC-conjugated
polyclonal antibodies to mouse IgG (Sigma Chemical Co.) and
mouse C3 (Cappel/ICN Biomedicals). Intensity of fluorescence
was graded from 0 to 
 
111
 
 on coded sections.
To monitor LPS induction of autoantibodies, mice (3 mo of
age) were immunized intraperitoneally with 30 
 
m
 
g LPS (
 
Escherichia
coli
 
 strain 0111:B4; Sigma Chemical Co.) four times at weekly in-
tervals, and IgG anti-dsDNA and total IgG levels were measured
by ELISA.
 
Results
 
To assess the spontaneous production of autoantibodies
in mice deficient in serum IgM, litter-matched cohorts of
 
m
 
s
 
2
 
/
 
m
 
s
 
2
 
 and 
 
m
 
s
 
1
 
/
 
m
 
s
 
1
 
 homozygote mice were monitored
for the development of serum IgG anti-dsDNA antibodies.
9 out of 30 
 
m
 
s
 
2
 
/
 
m
 
s
 
2
 
 mice developed titers of IgG anti-DNA
at an age of 12–18 mo that were 
 
.
 
3 SEM above the mean
titers observed in 
 
m
 
s
 
1
 
/
 
m
 
s
 
1
 
 controls (Fig. 1 A). None of the
21 control mice showed such elevated titers of autoantibody
(Fig. 1 A) nor have such autoantibodies been detected in
1-yr- (4) or 18-mo-old non–gene-targeted mice generated
from control F2 breedings (Fig. 1 A). The fact that IgG
anti-dsDNA is detected in sera from 
 
m
 
s
 
2
 
/
 
m
 
s
 
2
 
 mice but not
 
m
 
s
 
1
 
/
 
m
 
s
 
1
 
 controls cannot be attributed to any effect of serum
IgM antibodies in masking the detection of IgG anti-ds-
DNA, since a clear difference in IgG anti-dsDNA titers was
still evident if the assays were performed using purified se-
rum IgG fractions rather than total serum (Fig. 1 B). The
sera from the mice were also screened for autoantibodies by
 
Crithidia
 
 immunofluorescence: five mice scored strongly
positive, and these were from the animals harboring the
highest titer of IgG anti-dsDNA as judged by ELISA.
The quality of the anti-dsDNA antibodies was analyzed
by surface plasmon resonance. It is clear that the sera con-
tain a complex mixture of antibodies with different binding
characteristics. A minority of the initially bound antibody
dissociates rapidly to leave a residue that exhibits strong ds-
DNA binding, characterized by dissociation half-lives 
 
.
 
10
min (Fig. 1 D). This tightly bound antibody can be re-
vealed by developing after several minutes with an anti–
mouse IgG antiserum. Sera from control 
 
m
 
s
 
1
 
/
 
m
 
s
 
1
 
 mice
only exhibited the very rapidly dissociating DNA-binding
component (which is likely of the IgM isotype). ELISA
analysis also revealed that one of the IgM-deficient mice
that harbored IgG anti-dsDNA (mouse 9206) also scored
positive for anticardiolipin antibodies; furthermore, IgG
anticardiolipin and IgG antimyeloperoxidase antibodies
were also detected in 
 
m
 
s
 
2
 
/
 
m
 
s
 
2
 
 mice that had scored nega-
tive for IgG anti-dsDNA (Fig. 1 C). In contrast, no mice
positive for IgG antibodies to cardiolipin or myeloperoxi-
dase were identified in the control cohort.
The kidneys of the five IgM-deficient mice that con-
tained elevated anti-DNA antibodies as judged by the
 
Crithidia
 
 assay as well as the kidneys from eight control
mice were scored blindly for histopathological changes.
Though overt pathological disease was observed in only 1
mouse (number 9128; see Fig. 2), 6 of the 13 mice exam-
ined scored highly for IgG and/or C3 deposition (Table I).
Of these six animals, five (four at 
 
111
 
 and one at 
 
11
 
)
corresponded to the IgM-deficient mice that had been
Figure 1. (A) Titers of IgG
anti-dsDNA and total IgG in the
sera of 12–18-mo-old litter-
matched  ms
2/ms
2 and ms
1/ms
1
mice. A line at 0.24 U/ml marks
an IgG anti-dsDNA titer 3 SEM
above the average titer of the
ms
1/ms
1 controls. The IgG anti-
dsDNA titers in sera from 18–
20-mo-old mice generated from
control (129 3 C57BL/6)F2
breedings (labeled F2) are shown
for comparison. (B) Titers of IgG
anti-dsDNA in the IgG fraction
of sera of 12–18-mo-old litter-
matched ms
2/ms
2 and ms
1/ms
1
mice. The IgG fractions were
obtained by purification on pro-
tein G–Sepharose. (C) ELISA ti-
tration of autoantibodies in ms
2/
ms
2 mice. Open symbols are
from  ms
2/ms
2 mice, filled sym-
bols from representative ms
1/ms
1
controls. The ms
2/ms
2 sera illus-
trated harboring anti-dsDNA an-
tibodies are from mice 9128 and
9383; the two sera with elevated anticardiolipin antibodies are from mice 9206 (which also harbors IgG anti-dsDNA; see Table I) and 9484; the mouse
harboring antibodies to myeloperoxidase is 9296. (D) Binding kinetics of the anti-DNA antibodies as measured by surface plasmon resonance. Antibody
binding to a biotinylated dsDNA oligodeoxyribonucleotide immobilized on a streptavidin chip is depicted in resonance units and was monitored as a
function of time. After z4 min, residual IgG bound to the chip was identified using a polyclonal anti–mouse IgG antiserum. The dashed line depicts the
same experiment performed using serum from a control mouse that did not exhibit IgG anti-dsDNA. (E) Immunofluorescence of Crithidia with serum
(diluted 1:20) from ms
2/ms
2 mouse 9383 reveals characteristic staining of the nucleus and kinetoplast. 
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identified in the 
 
Crithidia
 
 assay, the kidney staining in three
of these mice being both in the capillary wall and the me-
sangium. The sixth mouse (scoring 
 
11
 
, mesangial staining
only) was a 
 
m
 
s
 
2
 
/
 
m
 
s
 
1
 
 heterozygote with a somewhat ele-
vated IgG anti-DNA titer.
As well as monitoring the spontaneous development of
autoantibodies, we wished to ascertain whether IgM defi-
ciency facilitated their experimental induction. Repeated
injection of bacterial LPS has been shown to lead not only
to an increase in serum IgG but also to the development of
anti-dsDNA antibodies and the enhancement of autoim-
mune disease in mouse models (5). Consistent with this,
LPS treatment leads to hypergammaglobulinemia in both
 
m
 
s
 
1
 
/
 
m
 
s
 
1
 
 and 
 
m
 
s
 
2
 
/
 
m
 
s
 
2
 
 3-mo-old mice but it is only among
the 
 
m
 
s
 
2
 
/
 
m
 
s
 
2
 
 animals that we detected enhanced production
of IgG anti-dsDNA (Fig. 3).
 
Discussion
 
Selective deficiency of serum IgM leads to delayed T
cell–dependent IgG responses to foreign antigens while at
the same time paradoxically increasing the tendency to de-
velop an IgG response to autoantigens.
The tendency to autoantibody development might be
explicable in terms of those perturbations of the immune
system in serum IgM–deficient mice that have already been
described. Thus, the mice exhibit augmented IgG re-
sponses to type 2 T cell–independent (TI-2) antigens (1, 2);
others have proposed an association between TI-2 type im-
mune responses and the induction of autoantibodies (6).
The serum IgM–deficient mice also harbor an increased
population of B-1 B cells (1, 2); such B cells have been im-
plicated in autoimmunity in some but not other mouse
models (see, for example, references 7 and 8).
While selective IgM deficiency in humans has been de-
scribed only rarely (9–11), selective deficiency in IgA in hu-
mans is relatively common and is associated with autoim-
munity (reviewed in 12, 13). The mechanistic basis of this
association is not unknown. Along the lines proposed for as-
sociation of certain infections with various organ-specific
autoimmune diseases, it has been postulated that the au-
toimmunity might arise as a consequence of the increased
number of infections suffered by IgA-deficient patients. A
 
Table I. IgG and C3 Deposition in Kidney
Serum IgG
anti-dsDNA
Kidney
deposition
Mouse no. ms ELISA
Crithidia
fluorescence IgG C3
U/ml
9116 2/2 0.08 21 1
9128 2/2 1.41 1 111 111
9383 2/2 1.74 1 111 11
9206 2/2 0.68 1 111 1
9397 2/2 0.53 11 1 1 1
9444 2/2 0.66 1 111 111
9461 2/2 0.08 21 1
9199 1/2 0.24 21 1 1 1
9332 1/2 0.10 22 1
9460 1/2 0.10 21 1
9288 1/1 0.11 21 1
9338 1/1 0.08 21 /21
9486 1/1 0.07 21 /21
MRL/lpr 111 111
NZB/W 111 111
Kidney staining was monitored on anonymized samples with scoring
ranging from 2 to 111. The staining, when apparent, was in the
mesangium although mice 9128, 9206, and 9383 also revealed IgG
deposition in the capillary wall.
Figure 2. IgG deposits in the kidneys of
ms
2/ms
2 mouse 9128 (and ms
1/ms
1 mouse
9332 as control) detected by immunohis-
tochemistry (original magnification: 3100;
1-s exposure).
similar logic could be applied to the IgM-deficient mice
since they exhibit enhanced sensitivity to microbial chal-
lenge (14); however, autoantibody production occurs spon-
taneously in serum IgM–deficient mice bred in a barrier unit
where the infection load is likely to be low. Furthermore, it
is far from clear that the association of autoimmunity with
IgA deficiency in humans actually reflects a role for the IgA
deficiency in triggering the autoimmunity: they could well
be independent consequences of a common cause. Indeed,
administration of LPS (which enhances autoantibody pro-1256 Autoimmunity in Secretory IgM-deficient Mice
duction in IgM-deficient mice) can trigger both IgA defi-
ciency and autoimmunity in mouse models (15).
We have previously interpreted the delayed maturation
of T-dependent immune responses in ms
2/ms
2 mice as re-
flecting a role for serum IgM, acting through complement,
in the handling of foreign antigens (2). This could be en-
acted by facilitating antigen localization to sites suitable for
immune response maturation or by costimulating B cell
signaling. Clearly, if IgM were to play an analogous role
with regard to the recognition of self-antigens during B cell
development, then serum IgM deficiency could lead to a
failure to recognize and delete some weakly autoreactive B
cell clones from the primary B cell repertoire, thus facilitat-
ing development of autoimmunity. Indeed, a predisposi-
tion to autoimmunity has already been described in both
humans and mice that are genetically deficient in compo-
nents of the complement cascade (16–18), and others have
previously interpreted this in terms of a role for comple-
ment in the negative selection of autoreactive B cells (17).
An alternative model is that the predisposition to autoim-
munity in IgM- or C-deficient individuals arises not so
much because an altered threshold setting allows the emer-
gence of autoreactive B cell clones but rather as a conse-
quence of alterations to the pathways and kinetics of anti-
gen clearance. This could be a result of the use of Fcg
rather than complement receptors or it could reflect an al-
tered size or site of deposition of immune complexes (for
example, see reference 19). This type of explanation, as-
cribing autoimmunity to an altered pattern of antigen han-
dling, shows parallels to some of the proposals made to ex-
plain antinuclear antibodies in mice deficient in serum
amyloid P component (20). A further possibility (which
follows similar thinking to Stewart et al. [21]) is that, in
normal mice, some IgM antibodies suppress the expansion
of autoreactive IgGs; this balance might then be perturbed
by IgM deficiency in serum.
Quite apart from the mechanism by which IgM defi-
ciency leads to autoimmunity, the observations raise the
question of whether IgM administration might be useful in
treatment of systemic autoimmunity. Nonspecific human
polyclonal IgG has been used with variable success to treat
patients suffering from diseases of presumed autoimmune
pathogenesis. It is possible that supplementing such IgG with
IgM may provide a useful adjunct for such therapy. Indeed,
polyclonal IgM supplementation of pooled IgG has recently
been shown to be effective in a rat nephritis model (22).
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A. Marshak-Rothstein, and J. Chen. 2000. Proc. Natl. Acad. Sci.
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